Exelixis Inc. diskutieren
Exelixis Inc.
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
20,62 €
-6,50 %
Buy Exelixis Inc.
Buy Exelixis Inc.
Buy Exelixis Inc.
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $24.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $23.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $25.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $29.00. They now have an "outperform" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $32.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $28.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $30.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $26.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $31.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at BTIG Research. They set a "buy" rating and a $27.00 price target on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Barclays PLC from $24.00 to $25.00. They now have an "overweight" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for EXEL provided by MarketBeat
Neueste Beiträge
StockNews_com in Fortinet Inc. diskutieren